{
    "clinical_study": {
        "@rank": "72260", 
        "acronym": "HNC", 
        "arm_group": [
            {
                "arm_group_label": "AlloVax", 
                "arm_group_type": "Experimental", 
                "description": "AlloVax(TM) - the intradermal injection of AlloSim(TM) followed immediately by the intradermal injection of CRCL weekly for 3 weeks followed by intravenous infusion of AlloStim(TM) in week 4 (cycle 1 = 4 weeks. Total 4 cycles)."
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "AlloVax(TM) placebo (the intradermal injection of AlloSim(TM) placebo followed immediately by the intradermal injection of CRCL placebo) weekly for 3 weeks followed by intravenous infusion of AlloStim(TM) placebo in week 4. (Cycle 1 = 4 weeks. Total 4 cycles)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of personalized\n      anti-cancer vaccine AlloVax(TM) in Subjects with confirmed recurrent or metastatic squamous\n      cell carcinoma of the head and neck (SCCHN) who cannot be treated with surgery, chemotherapy\n      or radiation. AlloVax(TM) is a personalized anti-cancer vaccine combining Chaperone Rich\n      Cell Lysate (CRCL) as a source of tumor antigen prepared from patient's tumor and\n      AlloStim(TM) as an adjuvant. The combination of CRCL and AlloStim(TM) is designed to provide\n      all the key components necessary to develop tumor-specific immunity creating the\n      inflammatory environment necessary to overcome the HNC immunosuppressive environment,\n      breaking tumor immune tolerance, and provision of specific HNC antigens for generation of a\n      specific adaptive anti-tumor response."
        }, 
        "brief_title": "Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer of Head and Neck", 
            "Squamous Cell Carcinoma of the Head and Neck"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double blinded, placebo controlled study. The subjects and\n      investigators will be blinded as to treatment arm.  All accrued subjects will undergo tumor\n      harvest procedures. The tumor samples will be processed into personalized Chaperone Rich\n      Cell Lysate (CRCL) vaccine. Subjects are assigned 3:1 ratio to AlloVax(TM) (CRCL with\n      AlloStim(TM)) or to placebo control arms. Both arms will receive best supportive care. Arm 1\n      will receive AlloVax(TM) (the intradermal injection of AlloSim(TM) followed immediately by\n      the intradermal injection of CRCL) weekly for 3 weeks followed by intravenous infusion of\n      AlloStim(TM) in week 4 (cycle 1). Arm 2 will receive AlloVax(TM) placebo weekly for 3 weeks\n      followed by an intravenous infusion of  AlloStim(TM)  placebo in week 4 (cycle 1). This\n      experimental treatment schedule will continue for 4 cycles."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult males and female patients aged 18 to 70 years old, inclusive, at screening\n             visit.\n\n          2. Patients with histopatholologically or cytologically confirmed diagnosis of recurrent\n             or metastatic squamous cell carcinoma of the head and neck (SCCHN) that is incurable\n             with surgery, chemotherapy or radiation. No nasopharyngeal primaries.\n\n          3. Patients must have a tumor safely accessable for surgical excision resulting in a\n             minimum of 0.5 g of tumor sample for CRCL processing.\n\n          4. Patients must have measurable disease according to revised RECIST v.1.1 guidelines\n             with at least one lesion deemed to be safely accessible for serial biopsy.\n\n          5. ECOG \u22642.\n\n          6. The result of screening test were in the criteria:\n\n             6.1 Adequate organ function including:\n\n             A. Marrow:\n\n               -  WBC >3000/mm3\n\n               -  Platelets >100,000/mm3.\n\n               -  Absolute neutrophil count \u2265 1,500/mm\u00b3\n\n               -  Hemoglobin \u2265 10.0 g/dL (transfusion allowed)\n\n             B. Hepatic:\n\n               -  Serum Total bilirubin < 2 x ULN mg/dL,\n\n               -  ALT (SGPT) / AST (SGOT) \u22643 x upper limit of normal (ULN).\n\n             C. Renal:\n\n               -  Serum creatinine (SCR) <2.0 x ULN, or\n\n               -  Creatinine clearance (CCR) >30 mL/min.\n\n             6.2 All patients have a pre-study echocardiogram without significant  abnormalities\n             or Ejection fraction >50%.\n\n             6.3 All patients must be screened to be negative for HIV1, HIV2, HTLVI, HTLVII, HBV,\n             HCV and RPR (syphilis).\n\n             6.4 Women of child-bearing potential must have a negative urine or serum pregnancy\n             test result within 72 hours prior to the start of study drug administration.\n\n          7. All patients of child producing potential must agree to use contraception or\n             avoidance of pregnancy measures while enrolled on study and receiving the\n             experimental product.\n\n          8. Patients must have the ability to understand the study, its inherent risks, side\n             effects and potential benefits and be able to give written informed consent to\n             participate.\n\n        Exclusion Criteria:\n\n          1. Clinical evidence or radiological evidence of nasopharyngeal primaries.\n\n          2. Clinical evidence or radiological evidence of brain metastasis.\n\n          3. History of severe hypersensitivity to monoclonal antibody drugs or any\n             contraindication to any of the study drugs.\n\n          4. Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple\n             sclerosis, autoimmune thyroid disease, uveitis).\n\n          5. Prior experimental therapy or cancer vaccine treatment (e.g., dendritic cell therapy,\n             heat shock vaccine).\n\n          6. Clinical requirement for systemic steroids or current immunosuppressive therapy,\n             including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month of\n             study entry.\n\n          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, requiring parenteral antibiotics, symptomatic congestive heart failure,\n             severe myocardial insufficiency, cardiac arrhythmia\n\n          8. All infections must be resolved and the patient must remain a febrile for seven days\n             prior to being placed in the study.\n\n          9. History of blood transfusion reactions.\n\n         10. Psychiatric or addictive disorders or other condition that, in the opinion of the\n             investigator, would preclude study participation.\n\n         11. Pregnant or breast feeding.\n\n        The patient will discontinuation from the participation in the study:\n\n          1. Less than 12 doses of CRCL able to be produced\n\n          2. Tumor sample for CRCL processing contains less than 80% tumor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998542", 
            "org_study_id": "ITL-010-HNC"
        }, 
        "intervention": [
            {
                "arm_group_label": "AlloVax", 
                "description": "Personalized anti-cancer vaccine Intradermal injection AlloSimt followed immediately by the intradermal injection of CRCL", 
                "intervention_name": "AlloVax", 
                "intervention_type": "Biological", 
                "other_name": "CRCL and AlloStim"
            }, 
            {
                "arm_group_label": "AlloVax", 
                "description": "autologous tumor-derived chaperone protein mixture", 
                "intervention_name": "CRCL", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Chaperone Rich Cell Lysate", 
                    "CRCL injection"
                ]
            }, 
            {
                "arm_group_label": "AlloVax", 
                "description": "AlloStim  (ID) injection AlloStim (IV) infusion", 
                "intervention_name": "AlloStim", 
                "intervention_type": "Biological", 
                "other_name": [
                    "AlloStim ID", 
                    "AlloStim IV"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Head and neck cancers", 
            "tumor vaccine", 
            "immunotherapy", 
            "personalized anti-cancer vaccine"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "link": [
            {
                "description": "Cancer", 
                "url": "http://www.nlm.nih.gov/medlineplus/cancer.html"
            }, 
            {
                "description": "Head and Neck Cancer", 
                "url": "http://www.nlm.nih.gov/medlineplus/headandneckcancer.html"
            }
        ], 
        "location": {
            "contact": {
                "email": "jksomjin@hotmail.com", 
                "last_name": "Somjin Chindavijak, MD", 
                "phone": "+66-2-3547025"
            }, 
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand"
                }, 
                "name": "National Cancer Institute of Thailand"
            }, 
            "investigator": [
                {
                    "last_name": "Somjin Chindavijak, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Wirote Lausoontornsiri, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ekapob Sangariyavanich, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Wilaporn Pagdeedindan, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I/II, Randomized Double-Blinded, Placebo-Controlled Study Designed To Evaluate Safety, Tolerability of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck.", 
        "overall_contact": {
            "email": "zivile@immunovative.co.il", 
            "last_name": "Zivile Katiliene, PhD", 
            "phone": "1-760-444-9040"
        }, 
        "overall_contact_backup": {
            "email": "thu@immunovative.co.il", 
            "last_name": "Thu Bui, MS", 
            "phone": "1-760-444-9040"
        }, 
        "overall_official": {
            "affiliation": "Immunovative Clinical Research, Inc", 
            "last_name": "Zivile Katiliene, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ministry of Public Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety and tolerability will be evaluated by physical exam, changes in laboratory values and patient reported symptoms.", 
            "measure": "To compare the safety and tolerability of AlloVax to the placebo", 
            "safety_issue": "Yes", 
            "time_frame": "From start of the treatment to 30 days after the last dose (it will be 5 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998542"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "23786302", 
                "citation": "Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis E, Graner MW. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperthermia. 2013 Aug;29(5):390-8. doi: 10.3109/02656736.2013.800997. Epub 2013 Jun 20."
            }, 
            {
                "PMID": "23734882", 
                "citation": "Mayer-Sonnenfeld T, Har-Noy M, Lillehei KO, Graner MW. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure. Int J Hyperthermia. 2013 Jun 4. [Epub ahead of print]"
            }, 
            {
                "PMID": "22075702", 
                "citation": "LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-\u03b3-dependent mechanism. J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9."
            }, 
            {
                "PMID": "21123824", 
                "citation": "Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1."
            }, 
            {
                "PMID": "18834631", 
                "citation": "Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2008 Sep 30; [Epub ahead of print]"
            }, 
            {
                "PMID": "18054441", 
                "citation": "Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2007 Dec 1; [Epub ahead of print]"
            }
        ], 
        "secondary_outcome": [
            {
                "description": "To study anti-tumor specific immune response to treatment.", 
                "measure": "Anti-tumor specific immune response", 
                "safety_issue": "No", 
                "time_frame": "30 days after the last dose"
            }, 
            {
                "description": "To study radiological and pathological changes.", 
                "measure": "Anti-Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "30 days after the last dose"
            }
        ], 
        "source": "Immunovative Therapies, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immunovative Therapies, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}